Company
ParcelBio
Elevated mRNA for transformative medicines
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
mRNA has already changed medicine. But the next generation of mRNA medicines – therapies that reprogram the immune system, kill tumors, and replace missing proteins – require a step-change in potency and durability. Conventional mRNA can't get there. APEXm™ can.
Funding snapshot
- Total raised
- $13MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Undisclosed, $13M2026-05-08
Funding rounds
- Round, 2026
- $13M2026-05-08, Company stated
Products
- Other
- APEXm™
Loading relationship preview